|
Index of reports
> Cases resulting in hospitalization (12)
> Cases with Pain (3)
Below is the selection of adverse event reports related to Estrace (Estradiol Vaginal) that includes cases resulting in hospitalization where reactions include pain.
Adverse event in 60 year old female receiving Estrace (Estradiol Vaginal)
Reported by a individual with unspecified qualification from United States on 2007-04-05
Patient: 60 year old female, weighing 68.0 kg (149.7 pounds)
Adverse reactions / side effects: Thrombosis, Therapeutic Procedure, Pulmonary Embolism, Chronic Obstructive Pulmonary Disease, Cyst Aspiration, Breast Cyst, Psychiatric Symptom, Proteinuria, Breast Microcalcification, Irritable Bowel Syndrome, Vaginal Burning Sensation, Benign Breast Neoplasm, Chondropathy, Pneumonia, Dysphagia, Pain in Extremity, Essential Tremor, Breast Mass, Osteopenia, Sacroiliitis, Lung Hyperinflation, Occult Blood Positive, Pulmonary Function Test Abnormal, Chondrocalcinosis, Rhonchi, Mental Disorder, Aortic Valve Disease, Vertigo Positional, Post Procedural Complication, Pain, Gastric Mucosal Hypertrophy, Carpal Tunnel Decompression, Urinary Tract Disorder, Ventricular Hypertrophy, Interstitial Lung Disease, Dizziness, Joint Arthroplasty, Injury, Sinusitis, Emphysema, Mitral Valve Disease, Dyspnoea, Calcinosis, Cystitis, Echocardiogram Abnormal, Atrophic Vulvovaginitis, Haematochezia, Gastrointestinal Pain, Diarrhoea, Blood Potassium Decreased, Pulmonary Thrombosis, Spinal Osteoarthritis, Lung Infiltration, Arthritis
Adverse event resulted in: hospitalization
Suspect drug(s):
Amen
Dosage: 10 mg, unk
Indication: Hormone Replacement Therapy
Start date: 1992-10-01
End date: 1996-08-01
Estrace
Dosage: 2 mg, qd
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1994-10-01
End date: 1994-11-01
Estraderm
Dosage: 1 mg, unk
Indication: Hormone Replacement Therapy
Start date: 1996-01-01
End date: 1996-10-01
MPA
Dosage: 10mg/5mg, unk
Indication: Hormone Replacement Therapy
Start date: 1994-01-01
End date: 1996-11-01
Ovcon-35
Premarin
Dosage: 1.25mg/2.5mg
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1992-01-01
End date: 1996-08-01
Premarin
Dosage: unk, unk
Indication: Atrophic Vulvovaginitis
Prempro
Dosage: 2.5mg/0.625mg
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1996-11-01
End date: 2001-01-01
Other drugs received by patient: Vioxx
Adverse event in 59 year old female receiving Estrace (Estradiol Vaginal)
Reported by a individual with unspecified qualification from United States on 2007-03-27
Patient: 59 year old female, weighing 96.1 kg (211.5 pounds)
Adverse reactions / side effects: Abdominal Pain, Abdominal Operation, Urinary Incontinence, Cervix Disorder, Incisional Hernia, Upper Respiratory Tract Infection, Central Venous Catheterisation, Postmenopausal Haemorrhage, Colostomy, Tendonitis, Rectal Prolapse, Breast Cancer, Enterostomy, Pelvic Abscess, Bursitis, non-Cardiac Chest Pain, Menopause, Cholelithiasis, Emotional Distress, Diverticulum, Vaginal Infection, Uterine Haemorrhage, Oophorectomy, Bladder Prolapse, Post Procedural Complication, Pain, Pelvic Pain, Cardiac Valve Disease, Hypercholesterolaemia, Ovarian Cystectomy, Fibrocystic Breast Disease, Basal Cell Carcinoma, Haemorrhagic Ovarian Cyst, Injury, Renal Failure Acute, Cataract, Mass, Urinary Tract Infection, Synovitis, Hernia, Tubal Ligation, Osteoarthritis, Adhesiolysis, Small Intestinal Resection, Radical Mastectomy, Uterine Prolapse Repair, Hypertension, Leukopenia, Abdominal Adhesions
Adverse event resulted in: hospitalization
Suspect drug(s):
Estrace
Dosage: 1 mg, qd
Administration route: Oral
Indication: Hormone Replacement Therapy
Start date: 1994-05-23
Estrace Vaginal Cream
Dosage: 2 g oncde per week
Indication: Menopausal Symptoms
Start date: 1994-04-27
Estrace Vaginal Cream
Dosage: 2 g once per week
Start date: 1994-05-23
Estraderm
Dosage: 0.1 mg, unk
Start date: 1999-08-02
Loestrin 1.5 / 30
Dosage: 1.5 mg, unk
Start date: 1994-09-08
Premarin
Dosage: 0.625 mg, qd
Administration route: Oral
Indication: Menopausal Symptoms
Start date: 1984-09-26
End date: 1997-10-01
Prempro
Dosage: .625/5 mg
Administration route: Oral
Indication: Menopausal Symptoms
Start date: 1997-06-25
End date: 2001-12-02
Provera
Dosage: 2.5 mg, qd
Administration route: Oral
Indication: Menopausal Symptoms
Start date: 1994-05-23
Provera
Dosage: 5 mg, qd
Administration route: Oral
Start date: 1996-01-02
End date: 1997-10-01
Other drugs received by patient: Prilosec; Avalide
Adverse event in 58 year old female receiving Estrace (Estradiol Vaginal)
Reported by a physician from United States on 2007-03-15
Patient: 58 year old female
Adverse reactions / side effects: Pulmonary Hypertension, Biopsy Breast Abnormal, Diabetes Mellitus, Dilatation Ventricular, Tricuspid Valve Incompetence, Treatment Noncompliance, Surgery, Atrial Hypertrophy, Oedema Peripheral, Breast Hyperplasia, Echocardiogram, Back Pain, Supraventricular Tachycardia, Breast Cancer Female, Cholelithiasis, Ventricular Dysfunction, Cholecystectomy, Homicidal Ideation, Scan Myocardial Perfusion Abnormal, Head Injury, Breast Cancer Stage IV, Pain, Hemiparesis, Fall, Fatigue, Fibrocystic Breast Disease, Coronary Artery Bypass, Dizziness, Lymphoedema, Atrial Flutter, Urinary Tract Infection, Atrial Fibrillation, Cerebrovascular Accident, Cardiac Pacemaker Insertion, Arthralgia, Mitral Valve Incompetence, Infarction
Adverse event resulted in: hospitalization
Suspect drug(s):
Curretab
Indication: Hormone Replacement Therapy
Start date: 1985-01-01
End date: 1995-01-01
Cycrin
Indication: Hormone Replacement Therapy
Start date: 1985-01-01
End date: 1995-01-01
Estrace
Indication: Hormone Replacement Therapy
Start date: 1985-01-01
End date: 1995-01-01
Estratest
Indication: Hormone Replacement Therapy
Start date: 1985-01-01
End date: 1995-01-01
MPA
Indication: Hormone Replacement Therapy
Start date: 1985-01-01
End date: 1995-01-01
Premarin
Dosage: 10 mg, unk
Administration route: Oral
End date: 1996-08-01
Prempro
Dosage: 0.625/25 mg, unk
Indication: Hormone Replacement Therapy
Start date: 1996-08-01
End date: 2002-08-01
Provera
Dosage: 0.625 mg, unk
Administration route: Oral
End date: 1996-08-01
Vivelle
Indication: Hormone Replacement Therapy
Start date: 1985-01-01
End date: 1995-01-01
|
